The ADAC technology was assessed by administrating a therapeutic conjugated dose s.c. on the opposite side of tumor engraftment to minimize direct CD40-mediated anti-tumor effect e.g., mainly focusing on an abscopal effect of the vaccination setting. The gene discussed is CD40; the disease is neoplasm.